Pieris, Sanofi Expand Development Pact

Pieris AG and The Sanofi Group have expanded their discovery and development partnership to include a novel multi-specific Anticalin program. The new program entitles Pieris to an upfront payment and committed research funding, as well as research, preclinical, regulatory and commercial milestones. Financial terms were not disclosed.
 
“Following more than two years of successful collaboration in this multi-program agreement, the expansion demonstrates that the Anticalin technology can deliver key differentiation over conventional biologic approaches, including the development of multi-specific targeted therapeutics,” said Stephen Yoder, chief executive officer of Pieris. “Sanofi and Pieris will continue to advance both existing and new programs, building on the excellent team chemistry between our organizations.”
 
Anticalin-branded proteins represent a novel generation of targeted protein therapeutics derived from human lipocalins, engineered to help solve for the pharmacological and pharmaceutical limitations of both protein- and non-protein-based drug platforms. Additional benefits include improved convenience, accelerated development timelines, ease of manufacturing and reduced cost.